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Abstract
Background: Lysophosphatidic acid (LPA) is a bioactive lipid inducing proliferation, differentiation as well as cytokine
release by mast cells through G-protein coupled receptors. Recently GPR92/LPA5 was identified as an LPA receptor highly
expressed by cells of the immune system, which prompted us to investigate its presence and influence on mast cells.
Principal Findings: Transcript analysis using quantitative real-time PCR revealed that LPA5 is the most prevalent LPA-
receptor in human mast cells. Reduction of LPA5 levels using shRNA reduced calcium flux and abolished MIP-1b release in
response to LPA.
Conclusions: LPA5 is a bona fide LPA receptor on human mast cells responsible for the majority of LPA induced MIP-1b
release.
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adaptive immunity, cardiovascular disease, and cancer (reviewed in
[1]). Their strategic localization around the microvasculature, in the
skin, and in the respiratory and gastrointestinal tracts situates them
ideally to be first responders to infectious agents and inflammatory
insults. Activated MCs release chemoattractants and mediators
affecting the vascular permeability, leading to plasma extravasation
and facilitating emigration of circulating inflammatory cells to the
site of MC activation. In allergic diseases, the most important
mechanism responsible for MC activation is cross-linking of the
high affinity IgE-receptor FceRI by allergens. MC-dependent
innate immune responses reflect their activation through several
receptors for bacterial products (e.g. toll-like receptor (TLR)-2,
TLR-4) and for complement fragments (e.g., C5a)[2,3]. The factors
that contribute to MC activation in cardiovascular disease and
cancer are unknown.
Lysophosphatidic acid (LPA) is a prominent lipid component of
serum that has pleiotropic effects in cell development, inflammation,
and cancer [4,5,6]. The biosynthesis of LPA involves either the
sequential action of secretory phospholipase A (sPLA) and lysopho-
spholipase D or phospholipase D followed by cytosolic PLA, and can
also be achieved by phosphorylation of monoacylglycerol (MAG) by
MAG kinases [7]. The most prominent pathway responsible for
maintaining extracellular LPA levels in the circulation stems from the
action of the lysoPLD known as autotaxin, an enzyme intimately
associated with the progression of tumors and metastasis [8]. LPA is
present in the serum at micromolar concentrations, circulating bound
to serum proteins, particularly to albumin and gelsolin. In response to
inflammation, LPA diffuses into the extravascular space, where it exerts
a wide variety of biological activities, including chemotaxis, prolifer-
ation, survival, cytokine and chemokine secretion, platelet aggregation
and smooth muscle cell contraction [9,10,11].
Many of the effects of LPA are mediated by specific cell surface
receptors. To date, eight G-protein coupled receptors (GPCRs) that
recognize LPA have been reported, including three members of the
endothelial differentiation and growth (Edg)-family (LPA1, LPA2, and
LPA3), and five of the purinergic (P2Y)-like family (LPA4 (GPR23),
LPA5 (GPR92), LPA6 (also known as P2Y5), P2Y10 and GPR87
[12,13,14,15,16,17,18,19]). We previously reported that human MCs
(hMCs) derived from cord blood express LPA1, LPA2, LPA3, and
LPA4 mRNA. hMCs proliferate and generate cytokines in response to
LPA, suggesting that LPA may be an activating ligand for MCs in
circumstances where it is abundant in the extravascular space, such as
cancer or myocardial infarction [4]. Based on experiments using
receptor-selective agonists and antagonists, LPA-induced proliferation
of hMCs was attributed to the functions of LPA1 and LPA3, whereas
cytokine generation reflected LPA2 [20]. Subsequent to those studies,
the orphan receptor GPR92 was found to bind LPA and was re-
designated as LPA5, and found to be particularly highly expressed on
cells associated with the immune system [21].
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18192In the present study, we demonstrate that LPA5 is the most
abundant LPA receptor expressed by human MCs at the mRNA
level. Using short hairpin RNA knockdown, we demonstrate that
LPA5 is involved in LPA-induced calcium flux, particularly at low
ligand concentrations, and crucial for the generation of the
chemokine macrophage inflammatory protein-1b (MIP-1b) re-
sponse to LPA. MIP-1b is a potent chemoattractant for, and
activator of, monocytes, lymphocytes and a wide variety of
immune cells [22]. We conclude that LPA5 may mediate a
pathway for MC activation in circumstances where cancers or




2 FAST SYBR Green (PA-042), RT
2 First strand kit (C-03)
and primers were from SABiosciences (LPA1; PPH02360A, LPA2;
PPH02343A, LPA3; PPH02354A, LPA4; PPH01859A, LPA5;
PPH12977A, P2Y10; PPH16348B, GPR87; PPH09602A,
GAPDH; PPH00150E). Antibodies directed against either an
extracellular epitope (LS-A425) or an intracellular epitope (LS-
A426) were from MBL International, whereas FITC-labeled goat
anti-rabbit IgG (554020) was from BD Biosciences.
TRI Reagent (T9424) was from Sigma-Aldrich.
Cell culture
The LAD2 line [23] isolated from the bone marrow of a patient
with MC leukemia was a gift from A. Kirshenbaum (National
Institutes of Health). These cells were cultured in StemPro-34
(Invitrogen, 10639-011) supplemented with 2 mM L-glutamine
(Invitrogen), 100 IU/ml Pen-strep (Invitrogen), and 100 ng/ml
stem cell factor (SCF; Thermo Fisher Scientific). Cell culture
medium was hemidepleted every week with fresh medium and
100 ng/ml SCF. Primary human cord blood MCs (hMCs) were
derived from cord blood mononuclear cells using SCF (100 ng/
ml), IL-6 (Peprotech, 200-06, 50 ng/ml), and IL-10 (Peprotech,
200-10, 10 ng/ml) as described [24] and used when .95% stained
with toluidine blue (typically 6 wk).
Cell activation
LAD2 cells were stimulated with the indicated concentrations of
LPA (D (+)-sn-1-O-oleoyl-glyceryl-3-phosphate, Echelon Biosci-
ence, UT, US) or were passively sensitized with 2 mg/ml of human
myeloma IgE (Millipore, AG30P-K) overnight and stimulated with
1 mg/ml of goat anti–human anti-IgE (Millipore, AP175) as
detailed elsewhere [25]; unstimulated LAD2 cells were used as
controls. The concentration of secreted MIP-1b in conditioned
media from LAD2 cells was measured by an ELISA (Invitrogen
CHC2293).
Calcium flux
Cells were washed once in cold HBSS, 1 mM CaCl2,1m M
MgCl2 (CM buffer) and subsequently resuspended at 1610
6 ells/
ml in CM buffer containing 2.5 mg/ml Fura 2-AM (Molecular
Probes) followed by incubation for 30 min at 37uC. Excess Fura 2-
AM was removed by washing twice with CM buffer, and the cells
were finally resuspended in CM buffer at 0.5610
6 cells/ml. Cells
were stimulated with the indicated concentrations of LPA, and
Figure 1. Expression of LPARs by LAD2 cells and hMCs. The expression of LPARs in hMC (A) and LAD2 (B) was assessed using SYBR green
based quantitative real-time PCR; transcript levels are normalized to the expression of GAPDH in individual samples (representative data of 3
determinations). Flow cytometric analysis was used to verify presence of LPA5 on the surface of unpermeabilized hMC (C) and LAD2 (D); grey tracing
represents isotype control whereas black tracing represents specific LPA5 staining. Mean fluorescence difference compared to isotype depicted in
insets of respective cell type (Mean MFI 6 SD, N=3 independent experiments, *P,0.05).
doi:10.1371/journal.pone.0018192.g001
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using excitation at 340 and 380 nm in a fluorescence spectropho-
tometer (F-4500; Hitachi). The relative ratios of fluorescence
emitted at 510 nm were recorded and displayed as a reflection of
intracellular calcium concentration.
Targeted suppression of LPA5 transcript
shRNA constructs were purchased from Open Biosystems
(Huntsville, AL). The constructs were designed to include a
hairpin of 21 base pair of a sense strand and an antisense strand,
and a 6 base-pair loop. The sequence of the most efficient
construct TRCN0000008981 was as follows:
59-CCGGGCTGTGCTTCGTGCCCTACAACTCGAGTT-
GTAGGGCACGAAG CACAGCTTTTT-39
Infectious viral particles were prepared by co-transfection of
293FT cells with an shRNA expressing plasmid, or a control
plasmid, and a lentiviral packaging mix (Virapower K4975-00;
Invitrogen) according to the manufacturer’s protocol. The viral
stocks were titered in HeLa cells and added to LAD2 cells
(0.25610
6 cell/ml; 1 ml, 24 well plate) at an MOI of 10. The
cells were incubated overnight with the particles at 37uC. The
following day, the medium was replaced and the cells were
cultured for an additional 48 hours before performing functional
studies.
Expression analysis
Total RNA was extracted from cells using TRI Reagent and
further purified using Qiagen RNEasy where a DNAse step was
included to eliminate genomic DNA contaminations. The RNA
concentration was determined by absorbance readings at 260 nm,
whereas the ratio of absorbance at 260/280 nm and 260/230 nm
was used to assess purity. 100 ng of samples with 260/280
readings of .1.8 and 260/230 readings of .1.9 were subsequently
converted into cDNA using RT
2 First strand kit according to the
manufacturer’s instruction. Transcript levels were determined
using a SYBR Green based system containing ROX as passive
reference and run on a Stratagene Mx3000p machine (95uC,
10 min; 40 cycles of 95uC, 15 sec; 60uC, 60 sec). The mRNA
expression was normalized to the expression of GAPDH in
individual samples.
Flow cytometry
Surface expression of LPA5 on LAD2 and hMCs was assessed
by staining non-permeabilized cells with a polyclonal antibody
(MBL International, LS-A425, diluted 25 times) followed by
incubation with a FITC-labeled goat anti-rabbit IgG (BD
Biosciences, 554020, diluted 200 times). The cells were detected
on a FACSCanto flow cytometer (BD Biosciences). Analysis was
conducted with FlowJo 7.2.
Figure 2. Functional responses in LAD2 induced by LPA. (A) Changes in intracellular calcium levels were determined using FURA-2AM loaded
LAD2 cells (1610
6 cell/sample) exposed to a range of concentrations of LPA (N=2 independent experiments). (B) Maximal calcium flux in (A)
represented in bar graph form; N=2, mean6 SEM. (C) Dose-dependent release of MIP-1b from LAD2 stimulated for 6 hours with IgE-crosslinking or
the indicated concentrations of LPA (N=3 independent experiments). Mean 6 SD. (D) LPA5 internalization in response to 1 mM LPA measured
15 min post stimulation determined by flow cytometric analysis. Filled grey tracing represents unperturbed cells whereas black tracing depicts LPA-
stimulated cells (representative of three experiments). The quantified reduction in MFI is shown in inset (Mean 6 SD, N=5, *P,0.0001).
doi:10.1371/journal.pone.0018192.g002
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Two-sided Student’s t-test.
Results and Discussion
Expression analysis of LPA receptors on MCs
The recent identification of LPA5 as being able to interact with
LPA prompted us to investigate its expression in human MCs.
Quantitative real-time PCR (qPCR) analysis revealed that mRNA
encoding LPA5 was the most abundant LPA receptor transcript in
both primary hMCs (Fig. 1a) and the well-differentiated MC
sarcoma line, LAD2 by several fold over LPA1, LPA2, LPA3,
LPA4, GPR87, P2Y5 and P2Y10) (Fig. 1b). Albeit less
differentiated compared to fully mature MCs, LAD2 cells and
primary hMCs serve as valid model systems for investigation of
MC [26]. To determine whether the LPA5 transcript was
translated into measurable amounts of protein, we used a
polyclonal antibody against this receptor in both flow cytometry
and western blot. We confirmed that LPA5 protein was readily
detected on the surface of both primary hMCs (Fig. 1c) and LAD2
Figure 3. Impact of shRNA based silencing on LPA5 transcript
and surface expression. (A) Transcript levels of LPA5 were
determined 72 h post transduction with either control vector or LPA5
shRNA in four independent experiments. (Mean 6 SD, N=7, *P,0.05)
(B) Transcript levels of a panel of LPARs were assessed to investigate
possible off-target effects of transduction with vector (black bars) or
LPA5 shRNA (white bars). (C) Surface expression of LPA5 after
transduction with empty vector (black tracing) or LPA5 shRNA (filled,
black tracing) compared to isotype control (grey tracing). The
quantified reduction in MFI, determined in three independent
experiments, is shown in inset (Mean 6 SD, N=5, *P,0.05).
doi:10.1371/journal.pone.0018192.g003
Figure 4. Influence of LPA5 silencing on functional responses
in LAD2 cells. (A) Calcium flux in response to the indicated
concentrations of LPA in control (grey tracing) or shRNA treated cells
(black tracing). (B) Maximum calcium flux in response to 1 mM LPA
represented in bar graph form (N=3 Mean 6 SD, *P,0.05). (C) MIP-1b
release six hours after exposure to 1 mM LPA from cells transduced with
control vector or LPA5 shRNA (N=3 Mean 6 SD, *P,0.05).
Determinations performed in three independent experiments.
doi:10.1371/journal.pone.0018192.g004
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comparable amount of transcript, an effect possibly due to
differences in culturing conditions, degree of maturation or
differences in regulation of translation. The observed differences
in expression could influence the relative ability of each cell type to
respond to LPA. Western blotting with the same antibody revealed
a single band of 42 kDa, consistent with the predicted size of the
LPA5 protein (not shown).
Contribution of LPA5 to LPA-induced signaling responses
in LAD2 cells
We had previously inferred functions of LPA1, LPA2, and
LPA3 receptors in LPA-induced activation and proliferation of
primary hMCs. Because of the growing number of known LPAR
receptors, the ability to discriminate functions of individual
receptors can be complicated by potential off-target effects of
inhibitors and agonists. We therefore used an RNA interference
(RNAi) approach to elucidate what biological influence LPA5 may
exert on MCs. Because LAD2 cells expressed LPA5 receptors at
levels comparable to that of primary hMCs and are easy to
maintain and transfect, we focused our analysis on this cell line.
LAD2 cells responded to LPA with a dose-dependent calcium flux,
an effect associated with subsequent chemokine generation
(Fig. 2a&b) [27]. Hence, we investigated whether LPA could
induce MIP-1b generation, which is a hallmark chemokine
associated with mast cell activation [28]. Exposing LAD2 cells to
increasing doses of LPA caused a dose-dependent release of MIP-
1b (Fig. 2c).Interaction between a ligand and its GPCR often
causes internalization of the receptor, and treatment of LAD2 cells
with 1 mM LPA for 15 minutes lead to a reduction of the levels of
LPA5 receptor at the cell surface (MFI=18.0860.13, N=4 vs.
MFI=14.7260.19, N=5, p,0.0001), suggesting some degree of
ligand-induced internalization (Fig. 2d). In contrast to murine
MCs [29], LAD2 cells did not degranulate in response to LPA as
determined by b-hexosaminidase release (data not shown).
At low concentrations (,0.5 mM), LPA induced a transient
increase in intracellular calcium levels in LAD2 cells, whereas
higher concentrations of LPA caused a sustained elevation of
calcium concentration. The concentration of LPA needed to
induce sustained calcium levels coincides with the dose of LPA
required for MIP-1b release, suggesting that an intracellular
calcium concentration threshold is involved in LPA-induced
generation of this chemokine.
To establish the role of LPA5 in mediating calcium responses
and cytokine generation in LAD2 cells, we transfected the LAD2
cells with a lentivirus encoding short hairpin (sh)RNA specifically
targeting the LPA5 transcript. This maneuver reduced LPA5
mRNA levels from a mean relative expression of 0.018 (vector
control) to 0.0037 (LPA5 shRNA) (Fig. 3a) with little influence on
other members of the LPAR family as determined by quantitative
real-time PCR (Fig. 3b). The reduction in transcript level was
associated with a similar result on protein level as shown by the
decrease in surface staining represented as fold difference over
isotype (Fold increase of MFI over isotype = 2.3460.41 N=3 vs.
1.4260.11 N=5, p=0.034) (Fig. 3c). Compared with LAD2 cells
treated with vector control, LPA5 shRNA-transfected LAD2 cells
showed slightly reduced calcium flux in response to LPA
(1.5460.31 vs. 0.6160.07 in response to 1 mM LPA, (Fig. 4a&b),
and demonstrated markedly reduced generation of MIP-1b
(535694 pg/ml vs 117614 pg/ml) that paralleled the reduction
in LPA5 expression (Fig. 4c).
Our findings indicated that LPA5 is the dominant LPA receptor
in hMCs under naı ¨ve conditions. In a previous study using
pharmacologic agonists, we had implicated LPA2 receptors in
LPA-mediated chemokine generation by primary hMCs. This
study predated the identification of LPA5 as an LPA receptor. It is
very likely that additional LPA receptors (such as LPA2) account
for the residual LPA-induced calcium flux observed in LAD2 cells
subjected to the knockdown of LPA5 (which resulted in a .80%
depletion of transcript and significant reduction in protein, Fig. 3).
Nonetheless, our data suggest that LPA5 is essential for LPA-
induced signaling events that result in MIP-1b generation. It seems
likely that LPA5 signals synergistically with other LPA receptors
on MCs, such as LPA2. The current study provides strong
evidence towards LPA5 being a functional LPA receptor on MCs,
and suggests that LPA5 may be important for conveying signals
leading to MIP-1b generation and release from MCs in contexts
where LPA levels are present in the tissues as a result of injury,
tumor invasion, or inflammation.
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